|
1
|
Kim C, Karvonen-Gutierrez C, Kong S,
Arends V, Steffes M, McConnell DS, Randolph JF Jr and Harlow SD:
Antimüllerian hormone among women with and without type 1 diabetes:
the Epidemiology of Diabetes Interventions and Complications Study
and the Michigan Bone Health and Metabolism Study. Fertil Steril.
Jul 28–2016.(Epub ahead of print). View Article : Google Scholar
|
|
2
|
Tully C, Aronow L, Mackey E and Streisand
R: Physical activity in youth with type 1 diabetes: a review. Curr
Diab Rep. 16:852016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hallford P, Clair DS, Halley L, Mustard C
and Wei J: A study of type-1 diabetes associated autoantibodies in
schizophrenia. Schizophr Res. 176:186–190. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Nasir H and Narasimhan S: Type 1 diabetes:
the need for culture-appropriate nutritional information for
carbohydrate counting. Lancet Diabetes Endocrinol. 4:8122016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Takashima S, Fujita H, Fujishima H,
Shimizu T, Sato T, Morii T, Tsukiyama K, Narita T, Takahashi T,
Drucker DJ, et al: Stromal cell-derived factor-1 is upregulated by
dipeptidyl peptidase-4 inhibition and has protective roles in
progressive diabetic nephropathy. Kidney Int. 90:783–796. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jojima T, Tomotsune T, Iijima T, Akimoto
K, Suzuki K and Aso Y: Empagliflozin (an SGLT2 inhibitor), alone or
in combination with linagliptin (a DPP-4 inhibitor), prevents
steatohepatitis in a novel mouse model of non-alcoholic
steatohepatitis and diabetes. Diabetol Metab Syndr. 8:452016.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Horowitz M, Wu T, Deane AM, Jones KL and
Rayner CK: DPP-4 inhibition and the known unknown. Diabetes.
65:2124–2126. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Itou M, Kawaguchi T, Taniguchi E and Sata
M: Dipeptidyl peptidase-4: a key player in chronic liver disease.
World J Gastroenterol. 19:2298–2306. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lamers D, Famulla S, Wronkowitz N, Hartwig
S, Lehr S, Ouwens DM, Eckardt K, Kaufman JM, Ryden M, Müller S, et
al: Dipeptidyl peptidase 4 is a novel adipokine potentially linking
obesity to the metabolic syndrome. Diabetes. 60:1917–1925. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Karagiannis T, Paschos P, Paletas K,
Matthews DR and Tsapas A: Dipeptidyl peptidase-4 inhibitors for
treatment of type 2 diabetes mellitus in the clinical setting:
systematic review and meta-analysis. BMJ. 344:e13692012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ishibashi Y, Matsui T, Maeda S,
Higashimoto Y and Yamagishi S: Advanced glycation end products
evoke endothelial cell damage by stimulating soluble dipeptidyl
peptidase-4 production and its interaction with mannose
6-phosphate/insulin-like growth factor II receptor. Cardiovasc
Diabetol. 12:1252013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Osawa S, Kawamori D, Katakami N, Takahara
M, Sakamoto F, Katsura T, Yasuda T, Kaneto H, Matsuhisa M, Matsuoka
TA, et al: Significant elevation of serum dipeptidyl peptidase-4
activity in young-adult type 1 diabetes. Diabetes Res Clin Pract.
113:135–142. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen C, Yu Q, Zhang S, Yang P and Wang CY:
Assessing the efficacy and safety of combined DPP-4 inhibitor and
insulin treatment in patients with type 2 diabetes: a
meta-analysis. Int J Clin Exp Pathol. 8:14141–14150.
2015.PubMed/NCBI
|
|
14
|
Mannucci E, Mosenzon O and Avogaro A:
Analyses of results from cardiovascular safety trials with DPP-4
inhibitors: cardiovascular outcomes, predefined safety outcomes,
and pooled analysis and meta-analysis. Diabetes Care. 39 Suppl
2:S196–S204. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Schnapp G, Klein T, Hoevels Y, Bakker RA
and Nar H: Comparative analysis of binding kinetics and
thermodynamics of dipeptidyl peptidase-4 inhibitors and their
relationship to structure. J Med Chem. 59:7466–7477. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kamiya H: A systematic review of the
benefits and harms of dipeptidyl peptidase-4 inhibitor for chronic
kidney disease. Hemodial Int. Jul 19–2016.(Epub ahead of print).
PubMed/NCBI
|
|
17
|
Scheen AJ: DPP-4 inhibitor plus SGLT-2
inhibitor as combination therapy for type 2 diabetes: from
rationale to clinical aspects. Expert Opin Drug Metab Toxicol.
29:1–11. 2016.
|
|
18
|
Katsuyama H, Fukunaga T, Hamasaki H,
Adachi H, Moriyama S, Kawaguchi A, Mishima S, Sako A and Yanai H:
The influences of withdrawal and daily dose reduction of
pioglitazone on metabolic parameters in patients with type 2
diabetes: a retrospective longitudinal observational study. J Clin
Med Res. 8:585–590. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Barry AR and Turgeon RD: DPP-4 inhibitors:
the Seinfeld of oral antihyperglycemics. Can J Hosp Pharm.
69:253–254. 2016.PubMed/NCBI
|
|
20
|
Li S, Xu H, Cui S, Wu F, Zhang Y, Su M,
Gong Y, Qiu S, Jiao Q, Qin C, et al: Discovery and rational design
of natural-product-derived
2-phenyl-3,4-dihydro-2H-benzo[f]chromen-3-amine analogs as novel
and potent dipeptidyl peptidase 4 (DPP-4) inhibitors for the
treatment of type 2 diabetes. J Med Chem. 59:6772–6790. 2016.
View Article : Google Scholar : PubMed/NCBI
|
